Safety reporting in chronic kidney disease clinical trials: a comparison of ClinicalTrials.gov registries and published reports
Transparent reporting of adverse events (AEs) is essential for evaluating the safety of interventions from chronic kidney disease (CKD), a population especially vulnerable to treatment-related harm because of polypharmacy, reduced renal clearance, and high comorbidity burden. Since 2007, the FDA Amendments Act (FDAAA 8...